ArticleFrontiers in aging neuroscience2026
Multimodal characterization of cortical hyperexcitability as a driver of cognitive decline in neurocognitive disorders: study protocol for the LENDÜLET Neurocognitive Research Project.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cognitive impairment is a major source of disability in neurodegenerative conditions, and it is also highly prevalent in autism spectrum disorder and attention-deficit/hyperactivity disorder. Across these conditions, subclinical epileptiform activity and resting-state functional hyperactivity have been repeatedly described, suggesting a shared state of cortical hyperexcitability. The LENDÜLET Neurocognitive Research Project aims to determine the incidence and multimodal characteristics of cortical hyperexcitability in multiple patient populations and to elucidate how hyperexcitability relates to cognitive performance, large-scale network connectivity, sleep-dependent memory consolidation, and tau/amyloid burden. Methods: In a prospective, multimodal observational study, we are recruiting 75 participants per group (patients with mild cognitive impairment, patients with autism spectrum disorder, patients with attention deficit/hyperactivity disorder, and healthy controls; total Anticipated results: Primary outcome is the incidence and distribution of cortical hyperexcitability in each diagnostic group relative to controls. Secondary outcomes include relationships between hyperexcitability and (a) structural atrophy and white matter integrity; (b) functional connectivity within and between default mode, salience, and attention networks; (c) cerebrospinal and plasma tau/amyloid levels; and (e) domain-specific cognitive performance. The current paper describes the study design, while the results are not reported. Discussion: This study will provide the first systematic, multimodal assessment of cortical hyperexcitability across multiple neurocognitive disorders with shared vulnerability to epilepsy and cognitive decline. The resulting biomarker panel may support risk stratification, inform clinical trial design for anti-hyperexcitability interventions, and ultimately enable individualized prevention strategies for cognitive decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.